Editas Medicine Stock Forecast

Stock Price Forecast

According to 13 analysts polled by S&P Global, Editas Medicine stock has a consensus rating of "Buy" and an average price target of $5.90. The average 1-year stock price forecast is 135.06% higher than the current stock price, while the lowest is $1.00 (-60.16%) and the highest is $15 (+497.61%).

Price Target: $5.90 (+135.06%)

Analyst Consensus: Buy

Price Target

Chart

Target	Low	Average	Median	High
Price	$1.00	$5.90	$5.00	$15
Change	-60.16%	+135.06%	+99.20%	+497.61%

Analyst Ratings

The average analyst rating for Editas Medicine stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Chart

Rating	Mar '26	Apr '26	May '26	Jul '26	Aug '26	Sep '26
Strong Buy	7	7	7	6	7	8
Buy	0	0	0	0	0	0
Hold	5	5	4	4	4	3
Sell	2	2	2	2	2	2
Strong Sell	0	0	0	0	0	0
Total	14	14	13	12	13	13

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Debjit Chattopadhyay Guggenheim	Guggenheim	Buy Upgrades $5	Buy	Upgrades	$5	+99.20%	Sep 23, 2026
Rick Bienkowski Ladenburg Thalmann & Co.	Ladenburg Thalmann & Co.	Buy Initiates $6	Buy	Initiates	$6	+139.04%	Aug 18, 2026
Alec Stranahan Bank of America Securities	Bank of America Securities	Sell Reiterates n/a	Sell	Reiterates	n/a	n/a	Aug 7, 2026
Luca Issi RBC Capital	RBC Capital	Hold Maintains $4	Hold	Maintains	$4	+59.36%	Aug 6, 2026
Mitchell Kapoor H.C. Wainwright	H.C. Wainwright	Buy Reiterates $3 → $5	Buy	Reiterates	$3 → $5	+99.20%	Aug 6, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

25.79M

from 40.52M

-36.34%

from 40.52M

Revenue Next Year

19.46M

from 25.79M

-24.56%

from 25.79M

EPS This Year

-0.83

from -1.80

EPS Next Year

-0.75

from -0.83

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	25.54M	19.71M	78.12M	32.31M	40.52M	25.79M
Revenue Growth	-71.85%	-22.83%	296.32%	-58.64%	25.40%	-36.34%
Operating Income	-193.15M	-225.95M	-169.18M	-238.92M	-99.34M	-97.15M
Net Income	-192.50M	-220.43M	-153.22M	-237.09M	-160.06M	-95.20M
EPS	-	-	-	-	-1.80	-0.83
Free Cash Flow	-	-	-	-	-165.85M	-94.00M
No. Analysts	-	-	-	-	-	12

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Chart

Revenue	2026	2027	2028
High	38.9M
Avg	25.8M
Low	16.7M

Revenue Growth

Chart

Revenue Growth	2026	2027	2028
High	-4.0%
Avg	-36.3%
Low	-58.7%

EPS Forecast

Chart

EPS	2026	2027	2028
High	-0.66
Avg	-0.83
Low	-0.99

EPS Growth

Chart

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-